Bloomberg Cites PHE Alzheimer’s Disease Study

A new attention-grabbing PHE study, commissioned by the Alzheimer’s Association, investigates the potential savings of obtaining an earlier diagnosis. As reported in Bloomberg, PHE’s study demonstrated that an increase in early diagnosis of Alzheimer’s would lead to significant savings for the US—potentially up to $7.9 trillion over the lifetimes of everyone alive right now.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.